JP2016500088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500088A5 JP2016500088A5 JP2015543424A JP2015543424A JP2016500088A5 JP 2016500088 A5 JP2016500088 A5 JP 2016500088A5 JP 2015543424 A JP2015543424 A JP 2015543424A JP 2015543424 A JP2015543424 A JP 2015543424A JP 2016500088 A5 JP2016500088 A5 JP 2016500088A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredient
- tolterodine
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 65
- 239000004480 active ingredient Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 17
- 238000013270 controlled release Methods 0.000 claims description 16
- 239000011324 bead Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 229960004045 tolterodine Drugs 0.000 claims description 12
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000001022 anti-muscarinic effect Effects 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 7
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 7
- 208000020629 overactive bladder Diseases 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 206010029446 nocturia Diseases 0.000 claims description 5
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002160 alpha blocker Substances 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000000859 sublimation Methods 0.000 claims description 4
- 230000008022 sublimation Effects 0.000 claims description 4
- 229960003553 tolterodine tartrate Drugs 0.000 claims description 4
- 239000000651 prodrug Chemical group 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical group C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 claims description 2
- 241000220479 Acacia Species 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 229960002845 desmopressin acetate Drugs 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229960002613 tamsulosin Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3575DE2012 | 2012-11-21 | ||
| IN3575/DEL/2012 | 2012-11-21 | ||
| IN3947/DEL/2012 | 2012-12-20 | ||
| IN3947DE2012 | 2012-12-20 | ||
| PCT/EP2013/074373 WO2014079922A1 (en) | 2012-11-21 | 2013-11-21 | Composition for immediate and extended release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016500088A JP2016500088A (ja) | 2016-01-07 |
| JP2016500088A5 true JP2016500088A5 (enExample) | 2016-11-17 |
Family
ID=49619947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015543424A Pending JP2016500088A (ja) | 2012-11-21 | 2013-11-21 | 即時放出および持続放出のための組成物 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2922525A1 (enExample) |
| JP (1) | JP2016500088A (enExample) |
| KR (1) | KR20150085826A (enExample) |
| CN (1) | CN104797240A (enExample) |
| AR (1) | AR093585A1 (enExample) |
| AU (1) | AU2013349682A1 (enExample) |
| BR (1) | BR112015011430A2 (enExample) |
| CA (1) | CA2891365A1 (enExample) |
| EA (1) | EA201590805A1 (enExample) |
| HK (1) | HK1213779A1 (enExample) |
| IL (1) | IL238648A0 (enExample) |
| IN (1) | IN2015DN03984A (enExample) |
| MX (1) | MX2015006399A (enExample) |
| PH (1) | PH12015501096A1 (enExample) |
| SG (2) | SG10201703388TA (enExample) |
| TW (1) | TW201422254A (enExample) |
| WO (1) | WO2014079922A1 (enExample) |
| ZA (1) | ZA201503603B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3024474T3 (da) | 2013-07-23 | 2022-03-28 | Serenity Pharmaceuticals Llc | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist |
| KR20150144209A (ko) * | 2014-06-16 | 2015-12-24 | 훼링 비.브이. | 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물 |
| EP3220942B1 (en) * | 2014-11-20 | 2022-04-27 | Serenity Pharmaceuticals LLC | Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist |
| BR112017014953A2 (pt) | 2015-01-12 | 2018-03-13 | Nano Pharmaceutical Laboratories Llc | microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| AU2016317092A1 (en) * | 2015-09-01 | 2018-04-26 | Wellesley Pharmaceuticals, Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
| SG11201805527QA (en) * | 2015-09-30 | 2018-07-30 | Wellesley Pharmaceuticals Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| WO2017058428A1 (en) * | 2015-09-30 | 2017-04-06 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
| EP3389661A4 (en) * | 2015-12-18 | 2019-12-18 | Wellesley Pharmaceuticals, LLC | COMPOSITION FOR REDUCING THE FREQUENCY OF URINATION, METHOD FOR THE PRODUCTION AND USE THEREOF |
| KR20220100077A (ko) | 2016-04-21 | 2022-07-14 | 발큐리아 에이비 | 암의 예비치료용 조성물 및 방법 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| KR20190104322A (ko) | 2017-01-11 | 2019-09-09 | 훼링 비.브이. | 속붕해성 약학적 조성물 |
| WO2019039836A2 (ko) * | 2017-08-22 | 2019-02-28 | 아주대학교산학협력단 | 퇴행성 신경질환 치료용 복합 제형 조성물 |
| US12389928B1 (en) * | 2024-10-25 | 2025-08-19 | Mccormick & Company, Inc. | Flavor-changing product |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4052997A (en) | 1996-07-19 | 1998-02-10 | Clarke-Garegg, Margaret A. | Levan derivatives, their preparation, composition and applications including medical and food applications |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| CA2484724C (en) * | 2002-05-07 | 2007-01-16 | Ferring B.V. | Pharmaceutical formulations |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科（北京）研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
| EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| WO2007029087A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Controlled release multiple unit formulations |
| US20090192228A1 (en) | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| CN102245171A (zh) * | 2008-11-10 | 2011-11-16 | 株式会社爱茉莉太平洋 | 缓释微粒及其制备方法 |
| WO2011013082A1 (en) * | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| CA2793485A1 (en) | 2010-03-29 | 2011-10-06 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| MX356601B (es) * | 2010-03-30 | 2018-05-29 | Productos Maver S A De C V | Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada. |
| US20120135050A1 (en) * | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2013
- 2013-11-11 TW TW102140886A patent/TW201422254A/zh unknown
- 2013-11-21 EP EP13792703.4A patent/EP2922525A1/en not_active Withdrawn
- 2013-11-21 KR KR1020157015219A patent/KR20150085826A/ko not_active Withdrawn
- 2013-11-21 CN CN201380060349.8A patent/CN104797240A/zh active Pending
- 2013-11-21 EA EA201590805A patent/EA201590805A1/ru unknown
- 2013-11-21 SG SG10201703388TA patent/SG10201703388TA/en unknown
- 2013-11-21 AR ARP130104308A patent/AR093585A1/es unknown
- 2013-11-21 WO PCT/EP2013/074373 patent/WO2014079922A1/en not_active Ceased
- 2013-11-21 SG SG11201503913TA patent/SG11201503913TA/en unknown
- 2013-11-21 CA CA2891365A patent/CA2891365A1/en not_active Abandoned
- 2013-11-21 IN IN3984DEN2015 patent/IN2015DN03984A/en unknown
- 2013-11-21 HK HK16101745.8A patent/HK1213779A1/zh unknown
- 2013-11-21 BR BR112015011430A patent/BR112015011430A2/pt not_active Application Discontinuation
- 2013-11-21 JP JP2015543424A patent/JP2016500088A/ja active Pending
- 2013-11-21 MX MX2015006399A patent/MX2015006399A/es unknown
- 2013-11-21 AU AU2013349682A patent/AU2013349682A1/en not_active Abandoned
-
2015
- 2015-05-05 IL IL238648A patent/IL238648A0/en unknown
- 2015-05-15 PH PH12015501096A patent/PH12015501096A1/en unknown
- 2015-05-21 ZA ZA2015/03603A patent/ZA201503603B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500088A5 (enExample) | ||
| EP3154523A1 (en) | Formulation for oral administration containing mesalazine | |
| SG184388A1 (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| ES2832699T3 (es) | Cápsulas recubiertas de liberación modificada | |
| US10213389B2 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
| CN107789626A (zh) | 用于缓解尿频的延长释放制剂及其使用方法 | |
| ES2831321T3 (es) | Cápsulas recubiertas de liberación modificada | |
| US20070243252A1 (en) | Oral Dosage Formulations and Methods of Preparing the Same | |
| HK1250628A1 (zh) | 用於遗尿的药物制剂及其使用方法 | |
| JP2016516031A5 (enExample) | ||
| HK1248549A1 (zh) | 用於缓解尿频的延长释放制剂及其使用方法 | |
| US20080069870A1 (en) | Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection | |
| CN103520136B (zh) | 孟鲁斯特钠脉冲胶囊及其制备方法 | |
| CN108135870A (zh) | 延缓、延迟和立即释放型制剂及其制造方法和用途 | |
| CN108391420A (zh) | 用于减少排尿频率的组合物及其制备方法和应用 | |
| US20070112075A1 (en) | Stable pharmaceutical formulations containing escitalopram and bupropion | |
| WO2013103357A1 (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| HK1259770A1 (en) | Composition for reducing the frequency of urination, method of making and use thereof | |
| HK1257452A1 (zh) | 缓解尿频的组合物，其制造方法和应用 | |
| MX2008004862A (es) | Formulaciones farmacéuticas estables que contienen escitalopram y bupropion | |
| KR20080031050A (ko) | 높은 ｐｈ-의존성 용해도를 갖는 활성 성분에 대해 활성성분이 ｐｈ-비의존적으로 지연 방출되는 제약 제제 | |
| HK1187241A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| AR064082A1 (es) | Composicion de liberacion modificada de al menos una forma de venlafaxina |